Literature DB >> 18476815

Standardized quantification of pulmonary fibrosis in histological samples.

Ralf-Harto Hübner1, Wolfram Gitter, Nour Eddine El Mokhtari, Micaela Mathiak, Marcus Both, Hendrik Bolte, Sandra Freitag-Wolf, Burkhard Bewig.   

Abstract

The Ashcroft scale for the evaluation of bleomycin-induced lung fibrosis is the analysis of stained histological samples by visual assessment. Based on the knowledge that this procedure is not standardized in animals and results are highly variable, we hypothesized that modification of this method may improve quantification of lung fibrosis in small animals. To prove our hypothesis, we evaluated pulmonary fibrosis in Lewis rats induced by a single intratracheal injection of 0.3 mg/kg body weight bleomycin (n = 13) compared with the same amount of saline in a control group (n = 4). We modified the Ashcroft scale by precisely defining the assignment of grades from 0 to 8 for the increasing extent of fibrosis in lung histological samples. Thirty-two observers were randomly assigned to evaluate 108 photographs of slides using either the Ashcroft scale or the modified scale. Consistent with our hypothesis, there was a significant reduction in the variability of standard deviations with the modified scale compared with the Ashcroft scale (mean of variability 0.25 versus 0.62, P < 0.0001). Applying the kappa index, the Ashcroft scale showed only a fair to moderate agreement (0.23-0.59) between the observers and a low intra-observer agreement (0.51-0.74) in contrast to the modified scale, which demonstrated a moderate to good agreement between the observers (0.65-0.93, P < 0.0001) and a high intra-observer agreement (0.87-0.91, P < 0.05). To test the modified scale in vivo, we compared both scales with the results of computed tomography (CT) of the lungs obtained from the same mice. In agreement, the modified scale demonstrated a better correlation to CT scans (R = 0.58) compared with the Ashcroft scale (R = 0.33). In summary, quantification of lung fibrosis in histological lung sections using the modified scale is reliable and reproducible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18476815     DOI: 10.2144/000112729

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  174 in total

1.  Differential effect of soy isoflavones in enhancing high intensity radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinoma.

Authors:  Gilda G Hillman; Vinita Singh-Gupta; David J Hoogstra; Lisa Abernathy; Joseph Rakowski; Christopher K Yunker; Shoshana E Rothstein; Fazlul H Sarkar; Shirish Gadgeel; Andre A Konski; Fulvio Lonardo; Michael C Joiner
Journal:  Radiother Oncol       Date:  2013-09-07       Impact factor: 6.280

2.  Bronchiolitis Obliterans and Pulmonary Fibrosis after Sulfur Mustard Inhalation in Rats.

Authors:  Matthew D McGraw; Marilyn M Dysart; Tara B Hendry-Hofer; Paul R Houin; Jaqueline S Rioux; Rhonda B Garlick; Joan E Loader; Russell Smith; Danielle C Paradiso; Wesley W Holmes; Dana R Anderson; Carl W White; Livia A Veress
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

3.  Peroxisome Proliferator-activated Receptor-γ Deficiency Exacerbates Fibrotic Response to Mycobacteria Peptide in Murine Sarcoidosis Model.

Authors:  Anagha Malur; Arjun Mohan; Robert A Barrington; Nancy Leffler; Amrita Malur; Barbara Muller-Borer; Gina Murray; Kim Kew; Chuanzhen Zhou; Josh Russell; Jacob L Jones; Christopher J Wingard; Barbara P Barna; Mary Jane Thomassen
Journal:  Am J Respir Cell Mol Biol       Date:  2019-08       Impact factor: 6.914

4.  Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation.

Authors:  Tingting Weng; Junsuk Ko; Chioniso P Masamha; Zheng Xia; Yu Xiang; Ning-Yuan Chen; Jose G Molina; Scott Collum; Tinne C Mertens; Fayong Luo; Kemly Philip; Jonathan Davies; Jingjing Huang; Cory Wilson; Rajarajan A Thandavarayan; Brian A Bruckner; Soma Sk Jyothula; Kelly A Volcik; Lei Li; Leng Han; Wei Li; Shervin Assassi; Harry Karmouty-Quintana; Eric J Wagner; Michael R Blackburn
Journal:  J Clin Invest       Date:  2019-02-28       Impact factor: 14.808

5.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

6.  Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease.

Authors:  Rebecca Lee; Charles Reese; Michael Bonner; Elena Tourkina; Zoltan Hajdu; Ellen C Riemer; Richard M Silver; Richard P Visconti; Stanley Hoffman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-28       Impact factor: 5.464

7.  Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis.

Authors:  Ram P Naikawadi; Supparerk Disayabutr; Benat Mallavia; Matthew L Donne; Gary Green; Janet L La; Jason R Rock; Mark R Looney; Paul J Wolters
Journal:  JCI Insight       Date:  2016-09-08

8.  Sirtuin 3 Deregulation Promotes Pulmonary Fibrosis.

Authors:  Meredith L Sosulski; Rafael Gongora; Carol Feghali-Bostwick; Joseph A Lasky; Cecilia G Sanchez
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-05-01       Impact factor: 6.053

9.  HDAC8 inhibition ameliorates pulmonary fibrosis.

Authors:  Shigeki Saito; Yan Zhuang; Takayoshi Suzuki; Yosuke Ota; Marjorie E Bateman; Ala L Alkhatib; Gilbert F Morris; Joseph A Lasky
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

10.  Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats.

Authors:  Nejat Altintas; Mustafa Erboga; Cevat Aktas; Bulent Bilir; Murat Aydin; Aysun Sengul; Zehra Ates; Birol Topcu; Ahmet Gurel
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.